Pharvaris N.V.
PHVSDrugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Jun 2027
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Deucrictibant
Hereditary Angioedema
Icatibant
Intradialytic Hypotension
Deucrictibant low dose
Hereditary Angioedema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Deucrictibant | Phase 3 | Hereditary Angioedema | - | - |
Icatibant | Phase 3 | Intradialytic Hypotension | - | - |
Deucrictibant low dose | Phase 2 | Hereditary Angioedema | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Pharvaris N.V.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Pharvaris N.V.'s (PHVS) pipeline across Phase 3, Phase 2. Its lead program is Deucrictibant (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharvaris N.V.'s next FDA catalyst?→
Pharvaris N.V.'s (PHVS) next tracked catalyst is a Phase 3 expected June 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PHVS biotech catalysts?→
Add PHVS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharvaris N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.